A Single Arm Study of Ipilimumab Monotherapy in Patients With Previously Treated Unresectable Stage III or IV Melanoma
Status:
Completed
Trial end date:
2007-07-01
Target enrollment:
Participant gender:
Summary
The purpose of this clinical research study is to evaluate the Best Overall Response Rate
(BORR), (as per modified WHO criteria) in patients with previously treated melanoma-Stage III
(unresectable) or Stage IV melanoma receiving 10 mg/kg of ipilimumab. The safety of this
product will also be evaluated.